NYXH:NASDAQNyxoah SA Analysis

Nyxoah SA (NYXH) is trading at roughly $1.60, well below its 52‑week high of $8.59 and the analyst median target of $8.88, indicating a potential upside of over 400%. The stock sits beneath its 20‑day ($2.18) and 50‑day ($2.71) simple moving averages, while the RSI of 31 suggests oversold conditions. However, the MACD remains in a bearish configuration and the broader trend is labeled bearish, signaling continued downside pressure in the near term. Recent capital actions—including a $95 million equity offering and a $15 million non‑dilutive loan—have bolstered the balance sheet, yet cash burn remains high with negative operating cash flow and a debt‑to‑equity ratio around 100%. The company’s flagship Genio hypoglossal neurostimulation system just earned the Prix Galien UK 2026 award, enhancing its credibility in the obstructive sleep apnea market. A search for a U.S.-based CEO aims to accelerate commercial rollout, which could unlock the sizable OSA addressable market.
While the valuation metrics (P/B ~1.7, price‑to‑sales ~10.4) and the extreme upside potential point to an undervalued stock, the high beta (>2), 30‑day volatility exceeding 200%, and persistent losses elevate the risk profile. Regulatory approval cycles and the need to transition from cash‑burn to profitability remain critical hurdles. Investors should weigh the upside against the substantial execution and liquidity risks before taking a position.